Ramsden

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

Editorial note — 7 September 2026. This page is a reading view recovered from a typeset PDF, and the recovery had flattened both data tables and most of the limitation headings into unreadable text. The tables and headings are restored here. Four substantive changes were made at the same time: the passage on anti-amyloid therapy has been corrected, since it lumped together trial classes with opposite results; a new Part V records three arguments against the framework that the original omitted — the APOE4–amyloid arm, the competing account of entorhinal vulnerability, and the Icelandic APP variant; the Validity Ledger has been extended to grade the amyloid reappraisal separately; and internal cross-references to an unpublished synthesis have been removed. The fuller and more current assessment of this framework is The Bond Not Made, which supersedes this page where the two differ.

---

Lipid Peroxidation and ApoER2–Dab1 Disruption in Sporadic Alzheimer's Disease

Abstract

Paradigm shift: amyloid cascade versus lipid peroxidation.

Amyloid cascade hypothesis	Lipid peroxidation hypothesis
APP cleavage	ApoE / lipid peroxidation
↓	↓
Aβ aggregation	ApoER2 crosslinking
↓	↓
Tau tangles	Dab1 / PI3K / GSK3β signalling failure
↓	↓
Neurodegeneration	pTau · PSD95 disassembly · Aβ secretion
	↓
	Neurodegeneration

While the traditional amyloid cascade posits Aβ accumulation as the primary driver of tauopathy and synaptic loss, the Ramsden hypothesis positions lipid peroxidation and APOE4 structural vulnerability as the initiating lesions. In this framework, receptor crosslinking disrupts Dab1 signalling, simultaneously triggering tau hyperphosphorylation, synaptic disassembly, and protective Aβ secretion.

The amyloid cascade hypothesis has dominated Alzheimer's disease (AD) research for decades, and the therapeutic return on it has been small in relation to the completeness of target removal. This analysis evaluates an alternative framework: that sAD is driven by peroxidation of apolipoprotein E (ApoE) and subsequent disruption of the ApoE receptor 2 (ApoER2) and Disabled homolog-1 (Dab1) signaling pathway.¹ The evaluation examines Ramsden and colleagues' hypothesis in light of historical, genetic, biochemical, and histopathological evidence. We assess the claim that the APOE4 allele's inability to form disulfide bonds leaves its polyunsaturated lipid cargo vulnerable to oxidative damage. Downstream peroxidation generates reactive lipid aldehydes that crosslink ApoE to ApoER2, disrupting endosomal recycling. This blockade starves the Reelin–ApoER2–Dab1 cascade, removing inhibition on GSK3β and LIMK1 kinases, which trigger tau hyperphosphorylation and postsynaptic density protein 95 (PSD95) disruption. We evaluate anatomical specificity via multiplex immunohistochemistry and consider whether this framework better explains the spatial evolution of tauopathy than prion-like spread models. We also reassess amyloid-beta (Aβ) as a possible protective response overwhelmed by chronic oxidative stress, and find that reassessment to be the weakest element of the framework and the one most clearly pressed by the human genetics.

Introduction

Sporadic Alzheimer's disease accounts for the majority of dementia cases globally. Unlike familial Alzheimer's disease, sAD is not causally linked to explicit genetic mutations in AβPP or presenilin. Anti-amyloid therapeutics have a mixed and instructive record: γ-secretase and BACE1 inhibitors worsened cognition, while the monoclonal antibodies lecanemab and donanemab slowed decline modestly and are the only interventions to date, among many mechanisms tried, that have altered the clinical course at all.²⁶ ²⁷ Accelerated brain volume loss following amyloid removal is a real observation whose interpretation remains contested. What the cascade model does not explain is why the benefit is so small in relation to how completely the target is cleared, and why the strongest genetic risk factor for the disease acts through a protein whose function is to carry lipid. The APOE ε4 allele is the single strongest genetic risk factor for sAD, yet the precise molecular mechanism linking this allele to disease risk remains disputed. The amyloid model also struggles to explain selective anatomical vulnerability of specific neuronal populations — entorhinal cortex layer II and locus coeruleus — to early neurofibrillary tangle formation, or the marked increase in lipid peroxidation that precedes plaque and tangle deposition.

Ramsden and colleagues (2022–2025) have articulated an alternative framework: the ApoE–ApoER2 peroxidation cascade hypothesis.⁸ They propose that peroxidation of polyunsaturated fatty acids transported by ApoE serves as an initiating molecular event in sAD. Reactive lipid aldehydes from this peroxidation crosslink ApoE to ApoER2, trapping ApoE in the extracellular space while disrupting intracellular Reelin–ApoER2–Dab1 signaling. This cascade disruption leads to destabilization of cytoskeletal elements and hyperphosphorylation of tau.¹ This analysis evaluates the theoretical coherence, empirical support, and histopathological validity of this framework.

Part I: Historical Context and Research Methods

ApoE Isoform Structural Variance and Lipid Protection Capacity

Isoform	Total cysteines	Disulfide bridge formation	Lipid protection status	AD risk profile
ApoE2	2	Super-ability (multimers)	Concealed and protected	Protective
ApoE3	1	Intermediate ability (dimers)	Concealed and protected	Baseline
ApoE4	0	Inability (monomer only)	Exposed to peroxidation	Highest risk

The presence of cysteine residues in ApoE2 and ApoE3 enables the formation of intermolecular disulfide bridges. These multimeric structures conceal and protect vulnerable PUFA cargo. ApoE4, lacking cysteine entirely, remains monomeric, leaving its lipid cargo exposed to severe peroxidation.

The Historical Record

Oskar Fischer's 1907 pathological study of 16 cases of senile dementia identified and characterized extracellular neuritic plaques in 12 patients. Fischer recognized these structures as disease-specific morphological substrates, arguing that plaques accounted for the clinical signs of dementia. This contrasted with earlier researchers who viewed plaques as byproducts of aging.

Fischer's contributions were marginalized through academic rivalry with the Munich school, which secured nomenclatural precedence for Alois Alzheimer's case presentation. Fischer's focus on senile dementia and plaques was sidelined in favor of Alzheimer's emphasis on tangles and early-onset cases.

Fischer was stripped of his academic positions, arrested by the Gestapo, and perished in Theresienstadt in 1942. His historiographical rehabilitation, initiated primarily by Michel Goedert in 2009, is relevant to current discourse: recent multiplex immunohistochemistry shows that neuritic plaques are the locus where peroxidized ApoE, sequestered Reelin, and disrupted ApoER2–Dab1 components co-accumulate.

Early Recognition of Oxidative Stress

Following biochemical sequencing of Aβ and tau in the 1980s, the amyloid cascade hypothesis achieved dominant status. However, dissenting researchers continuously highlighted unexplained phenomena: Markesbery, Butterfield, and colleagues demonstrated in the late 1990s and early 2000s that lipid peroxidation precedes overt plaque and tangle deposition, particularly in patients with amnestic mild cognitive impairment.¹ The human brain is uniquely susceptible to lipid peroxidation due to high oxygen consumption, modest antioxidant defenses, and dense concentrations of polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid). Peroxidation of these PUFAs generates reactive electrophilic aldehydes: 4-hydroxy-2-nonenal (4-HNE), malondialdehyde (MDA), and acrolein. These aldehydes covalently modify proteins by targeting histidine, lysine, and cysteine residues.

Crucially, Montine et al. (1997) observed that accumulation of 4-HNE adducts in the AD brain correlated with APOE4 inheritance, providing an early bridge between genetic risk and oxidative damage.

Research Methodology

Evaluation of the hypothesis relies on multiplex fluorescence immunohistochemistry (MP-IHC), developed by Maric and colleagues, which permits sequential probing of dozens of biomarkers on a single 6-micron tissue section. Traditional single-marker immunohistochemistry allows visualization of only 3–4 biomarkers, forcing researchers to use serial slices to infer co-localization. MP-IHC overcomes this limitation through iterative rounds of immunostaining, multispectral imaging, computational registration at subpixel resolution, and antibody stripping.

Empirical data assessed here derive from heavily vetted postmortem cohorts (Banner Sun Health Research Institute, University of Auckland, University of Kentucky). Specimens were procured via rapid-autopsy protocols with mean postmortem intervals of approximately 3 hours. Minimal formaldehyde fixation (48 hours) and rapid procurement preserve phosphorylation states of kinases under investigation.

Part II: Molecular Mechanism

ApoE Structure and the Lipid-Protecting Disulfide Bridge Hypothesis

ApoE is the principal lipid transporter in the central nervous system, synthesized primarily by astrocytes. It traffics cholesterol and polyunsaturated phospholipids to neurons for membrane maintenance and dendritic spine remodeling.

Humans possess three major APOE alleles — ε2, ε3, ε4 — differing by one or two amino acids at positions 112 and 158. APOE4 carriers face dose-dependent increased risk of sAD, while APOE2 is considered neuroprotective. The precise mechanistic linkage between these single amino acid substitutions and neurodegenerative risk remained unclear.

In 2025, Ramsden, Cutler, Li, and Keyes proposed a biochemical explanation: the "lipid-protecting disulfide bridge" hypothesis. The amino acid substitutions involve cysteine-arginine exchanges. ApoE2 contains two cysteines (Cys112, Cys158); ApoE3 contains one (Cys112); ApoE4 contains none, possessing arginines at both positions.

Cysteine's free thiol group enables formation of covalent intermolecular disulfide bridges.¹⁰ Independent research confirms that ApoE2 and ApoE3 form disulfide-linked homodimers, multimers, and heterodimers in cerebrospinal fluid and brain parenchyma. ApoE4, lacking cysteines, cannot form these bridges and exists as a monomer.

Ramsden's hypothesis proposes that disulfide-linked complexes shield polyunsaturated fatty acid cargo within a tightly packed hydrophobic core, protecting reactive carbon-carbon double bonds from reactive oxygen species. ApoE4, unable to dimerize, leaves PUFA cargo structurally exposed. In the aged brain's oxidative environment, this cargo undergoes accelerated peroxidation, decomposing into toxic electrophilic aldehydes (MDA, 4-HNE, acrolein).

Biochemical Crosslinking at the Receptor Interface

Neurons internalize ApoE and lipids primarily via the low-density lipoprotein receptor family, specifically Very-Low-Density Lipoprotein Receptor (VLDLR) and ApoE Receptor 2 (ApoER2). These receptors are positioned at the postsynaptic density and serve dual functions: lipid internalization and transmembrane signaling for Reelin.¹ Reelin is an extracellular glycoprotein secreted by specialized interneurons and projection neurons, essential for synaptic plasticity, dendritic spine formation, and memory consolidation.¹ The interface where both ApoE and Reelin bind to ApoER2 presents biochemical vulnerability. The ligand-binding domains of human ApoER2 are enriched in double-lysine motifs and histidine residues. These differ significantly from rodent models, potentially explaining why transgenic mice often fail to replicate human sAD pathology without artificial overexpression.

Lysine and histidine are primary targets for reactive lipid aldehydes. In vitro analyses show that exposure of ApoE and ApoER2 peptides to these aldehydes generates irreversible lipid-protein adducts.¹ More critically, bifunctional aldehydes act as chemical bridges, forming covalent, acid-stable pyrrole crosslinks between lysine and histidine residues of ApoE and ApoER2.

Intracellular Cascade Disruption

Under normal conditions, the ApoE–ApoER2 complex is rapidly internalized into the early endosome.¹ Within the acidic environment (pH ~6.0), the receptor undergoes conformational change that releases the ligand, and empty ApoER2 recycles back to the cell surface.

Aldehyde-induced pyrrole crosslinks between peroxidized ApoE and ApoER2 are stable in low pH environments. Consequently, the ApoE–ApoER2 complex becomes permanently fused, disrupting the pH-dependent dissociation process. This arrests receptor recycling and traps receptors within enlarged endolysosomal compartments — an established early pathological hallmark of sAD.¹

With receptors sequestered and the synaptic surface depleted of functional ApoER2, Reelin is blocked from binding. The downstream intracellular cascade collapses.

Kinase Cascade Consequences

Under healthy conditions, Reelin binding to ApoER2 triggers rapid tyrosine phosphorylation of the intracellular adaptor protein Disabled homolog-1 (Dab1) via Src and Fyn kinases.¹ This propagates the signal and simultaneously targets Dab1 for rapid ubiquitination and proteasomal degradation, providing negative feedback.

When peroxidized ApoE crosslinks and occludes ApoER2, Reelin signaling is entirely blocked. Because Dab1 degradation depends on active Reelin signaling, Dab1 aberrantly accumulates within dystrophic neurites. High-resolution MP-IHC studies show massive, globular Dab1 accumulations near neuritic plaques, serving as a biochemical marker of ApoER2 signaling failure.

Phosphorylated Dab1 normally recruits phosphoinositide 3-kinase (PI3K), specifically its regulatory subunit P85α, which activates Protein Kinase B (Akt). This PI3K/Akt pathway inhibits Glycogen Synthase Kinase 3 beta (GSK3β). Concurrently, Reelin–Dab1 signaling activates LIM domain kinase 1 (LIMK1), which phosphorylates cofilin, stabilizing the dendritic actin cytoskeleton and maintaining dendritic spine structure.

The starvation of this pathway removes essential molecular brakes. Failure to activate LIMK1 disrupts cofilin regulation, leading to collapse of dendritic actin cytoskeleton and formation of actin-cofilin rods. Simultaneously, without Akt-mediated inhibition, GSK3β becomes hyperactive, aggressively hyperphosphorylating tau at multiple epitopes (Ser202/Thr205), causing tau detachment from microtubules, microtubule depolymerization, axonal transport failure, and aggregation into neurofibrillary tangles.

Hyperactive GSK3β also phosphorylates postsynaptic density protein 95 (PSD95) at Threonine-19. PSD95 is the master scaffolding protein of the excitatory postsynaptic density, anchoring NMDA and AMPA receptors. Phosphorylation at Thr19 induces disassembly and internalization of excitatory postsynaptic receptor complexes, driving synaptic depression and memory loss.

Part III: Anatomical Specificity and Disease Evolution

Limitations of the Prion-Like Spread Model

The "prion-like spread" hypothesis argues that pathogenic, misfolded tau originates in a single location and propagates trans-synaptically across connected brain networks. However, this model has logical deficits when mapped against human neuroanatomy:

Tau pathology reliably spreads from the entorhinal cortex to the CA1 region while sparing the dentate gyrus granule cells for years, despite the dentate gyrus being the massive, direct synaptic target of the entorhinal cortex's perforant pathway. Early pTau pathology classically originates in the locus coeruleus before appearing in the entorhinal cortex. Yet locus coeruleus axons project diffusely across virtually the entire neuroaxis; they do not selectively innervate the entorhinal cortex. Early pTau pathology frequently isolates in distal dendritic tips of rare, solitary layer III and V neocortical pyramidal neurons, completely sparing immediately adjacent, heavily interconnected neurons — difficult to reconcile with broad synaptic diffusion.

Localized Vulnerability via ApoER2 Expression

The ApoER2–Dab1 disruption hypothesis offers an alternative explanation: tau is locally generated within specific, disparate neurons independently driven into signaling failure.¹ Their vulnerability is determined by: (1) exceptionally high expression of ApoER2, and (2) intense, continuous metabolic demand for lipid-membrane remodeling.¹ Using high-resolution MP-IHC, Ramsden's team mapped ApoER2 expression across 64 rapidly autopsied human brains spanning the spectrum of sAD. ApoER2 is highly expressed in the exact anatomical regions exhibiting earliest pTau pathology: stellate neurons of entorhinal cortex layer II; the ProS-CA1 border region of the hippocampus; the pontine locus coeruleus and raphe nucleus; and solitary layer III/V neocortical pyramids. Recent preprints (2024/2025) demonstrate similar ApoER2–Dab1 disruption in the amygdala, correlating with neuropsychiatric manifestations.

Region	ApoER2 expression	Tau onset	Prion-spread compatibility
Locus coeruleus	Extremely high	Pre-tangle (earliest)	Low (diffuse projections)
ErC layer II	Extremely high	Braak stage I	Low (retrograde to flow)
ProS-CA1 border	High	Braak stage II	Low (spares adjacent neurons)
Dentate granule cells	Low / moderate	Braak V/VI (late)	Low (direct target, spared early)
Neocortical L3/L5	High (apical tufts)	Braak I/II	Low (spares neighbours)
Neocortical L4	Absent	Spared	High (resistance predicted)

Crucially, MP-IHC shows that pTau does not appear in isolation. In mild cognitive impairment and sAD brains, pTau co-accumulates within ApoER2-expressing neurons alongside undegraded Dab1, phosphorylated P85α, and phospho-LIMK1. This co-accumulation of stalled signaling kinases provides evidence that the Reelin–ApoER2–Dab1 pathway has suffered upstream blockade, triggering local rather than transmitted neurodegeneration.

Part IV: Extracellular Consequences and Amyloid-Beta Reappraisal

Extracellular Accumulation and Plaque Formation

MP-IHC imaging of human sAD tissue reveals that ApoER2 ligands — native ApoE, lipid-peroxidation-modified ApoE (HNE-ApoE), ApoJ, and Reelin — accumulate in the extracellular space.¹ Because crosslinked ApoE–ApoER2 complexes cannot be internalized and processed by endolysosomal machinery, these peroxidized toxic lipoproteins build up within the synaptic cleft, forming the dense cores of neuritic plaques identified by Fischer a century ago.

Reconsidering Amyloid-Beta

Rather than acting as the pathological initiator of disease, Aβ secretion may initially serve as a protective physiological response.¹ At physiological (sub-nanomolar) concentrations, Aβ acts as a lipid-soluble antioxidant and transition metal chelator. BACE1, the rate-limiting enzyme in AβPP cleavage producing Aβ, is a stress-response protein upregulated by oxidative stress and lipid peroxidation.¹ Ramsden hypothesizes, in a claim first made in the 2020 prize submission,²⁵ that as peroxidized ApoE particles accumulate extracellularly due to receptor failure, neurons upregulate BACE1 to secrete Aβ monomers to bind, chelate, and neutralize toxic, oxidized lipid cargo, preparing it for glial clearance.¹ This model explains why ApoE is consistently enriched in the central core of newly formed Aβ plaques, with Aβ forming the surrounding corona.

However, under chronic, unrelenting oxidative assault — exacerbated by absent disulfide-bridge protection in APOE4 carriers — this protective mechanism becomes overwhelmed. High Aβ concentrations overcome solubility limits, oligomerize, form insoluble plaques, trigger microglial and astrocytic inflammatory responses, and transition from neuroprotective antioxidants to neurotoxic aggregates.

Part V sets out three arguments against this reappraisal. It is the weakest element of the framework, and the framework does not depend on it.

Therapeutic Implications

The clinical prediction that follows from a protective reading of amyloid — that lowering it should be neutral or harmful — has now been tested, and the direction did not hold. Lecanemab and donanemab both slowed clinical decline in early Alzheimer's disease.²⁶ ²⁷ The effects are small, the harms real, and their clinical meaningfulness is genuinely disputed; but the sign is positive, and amyloid immunotherapy remains the only mechanism among many tried that has moved the clinical course at all.

What must be kept separate from that record is the class of trials that did make patients worse. γ-secretase inhibition worsened cognition — and γ-secretase performs well over a hundred substrate cleavages, so the deficit cannot be attributed to amyloid lowering as such. BACE1 inhibitors likewise produced cognitive worsening, and BACE1 also carries a substantial physiological substrate list. The two classes that harmed patients were broad enzyme inhibitors; the class that helped removed the aggregate. Lumping the three together as "anti-amyloid therapy failed" discards the one comparison in the record that carries information.

The residual claim this framework can still defend is narrower, and worth stating precisely: nothing in the trial record establishes that lowering the amyloid-β monomer is beneficial, and the two interventions that lowered monomer production by inhibiting a promiscuous protease are the ones that harmed. That is an argument about which pool to target, not an argument against targeting amyloid.

Future therapeutic pipelines should, on this framework, prioritize stabilization of the Reelin–ApoER2–Dab1 signaling axis and mitigation of lipid peroxidation alongside amyloid-directed approaches rather than in place of them. Potential interventions include:

• Development of targeted ApoER2 agonists to bypass occluded receptors and restart the Dab1–PI3K survival cascade
• Deployment of lipid-soluble antioxidant scavengers designed to quench reactive aldehydes (4-HNE, acrolein) before irreversible pyrrole crosslinks form
• Advanced gene-editing therapeutics to restore disulfide-bridge functionality in APOE4 carriers

Part V: What the Framework Leaves Out

Three arguments run against the account above. None of them was engaged in the original analysis, and the first two are stronger than anything in the section on limitations that follows.

The stronger arm of the APOE effect

The framework routes APOE4 to tau and leaves amyloid-β largely to one side. That ordering omits the better-evidenced of the two arms. ApoE4 increases brain amyloid-β pathology relative to the other isoforms, and the great majority of the ApoE literature rests on that relationship rather than on a direct effect on tau.²⁸

The contrast that makes the point cheaply is frontotemporal lobar degeneration. Pick's disease and its relatives are tauopathies without amyloid pathology, and the APOE4 effect there is far smaller than in Alzheimer's disease. If APOE4 acted on tau principally by the route this framework proposes — receptor occlusion releasing GSK3β — a strong APOE4 effect on a pure tauopathy would be expected, and nothing of Alzheimer magnitude is observed.

The qualification is that the tau arm is real, and is simply secondary. Shi and colleagues showed that ApoE4 markedly exacerbates tau-mediated neurodegeneration in P301S mice independently of amyloid-β pathology, that ApoE knockout is protective, and — in the same study — that in people with a sporadic primary tauopathy an ε4 allele is associated with more severe regional neurodegeneration.²⁸ That result cuts in both directions. It establishes an amyloid-independent ApoE→tau arm of the kind this framework requires, and it locates a measurable APOE4 effect inside primary tauopathy, which softens the Pick's argument. What it does not do is make the tau arm the primary one. A framework that assigns the whole APOE4 effect to tau owes an account of the amyloid arm, and this one does not offer one.

A second tenant in the entorhinal map

The anatomical argument turns on ApoER2 expression matching the map of earliest tau. But entorhinal layer II stellate neurons are not an unclaimed address. They are the most heavily documented site of intraneuronal amyloid-β42 accumulation in the human brain. Gouras and colleagues reported Aβ42 accumulating within neurons in exactly these vulnerable regions, in a distribution that appears to precede both plaques and tangles;²⁹ Takahashi and colleagues then localised that peptide by immuno-electron microscopy to multivesicular bodies inside synaptic terminals, associated with abnormal synaptic structure before plaque pathology was present.³⁰

The selective vulnerability of this population therefore has at least two candidate explanations with human tissue evidence behind them. A correlation between ApoER2 expression and early tau does not by itself discriminate between them, and the analysis above presented one without naming the other.

A related point of priority belongs in the same place. Arrest of endosomal recycling in APOE4 carriers is not an observation this framework introduced. Cataldo and colleagues reported that endocytic-pathway abnormalities precede amyloid deposition in both sporadic Alzheimer's disease and Down syndrome, with differential effects by APOE genotype, in 2000.³¹ The framework's contribution is a proposed chemistry for that arrest — not the arrest itself.

BACE1, and the variant that argues against protection

Two corrections to the amyloid reappraisal in Part IV.

First, BACE1 is not solely a stress-response enzyme. It has constitutive physiological substrates — among them neuregulin-1, seizure protein 6, and the cell-adhesion molecules CHL1 and contactin-2 — and it is required for normal myelination and axonal guidance. Calling it a stress enzyme captures its inducibility and omits its day job, and the omission matters: BACE1's substrate breadth is the reason cognitive worsening under BACE1 inhibition cannot be read as evidence that amyloid is protective.

Second, and harder for the protective reading: the Icelandic APP variant. Jonsson and colleagues identified a coding substitution, A673T, adjacent to the β-secretase site, which reduces formation of amyloidogenic peptides by approximately 40 per cent in vitro, and which protects carriers both against Alzheimer's disease and against cognitive decline in old age in the absence of Alzheimer's disease.³² If amyloid-β at physiological concentration were principally a protective antioxidant, a lifelong reduction of that size ought to cost its carriers something. It does not.

Three qualifications belong on the record rather than in a footnote. The variant reduces β-cleavage from birth, which is not the same experiment as clearing deposited amyloid in the ninth decade. The substituted peptide has also been reported to aggregate less readily, so the variant is not a clean test of concentration alone. And the framework's claim concerns the monomer at physiological concentration rather than the total pool. Even after all three, this is the strongest single piece of human genetic evidence against the protective reading, and the analysis above did not engage it.

What This Analysis Cannot Determine

Causal versus correlative relationships. While MP-IHC demonstrates co-accumulation of pathway components, proving that ApoER2 occlusion directly causes (rather than correlates with) downstream kinase activation requires additional evidence. Cross-sectional autopsy data cannot establish directionality of causation without in vivo or experimental validation.

Initiating event timing. The hypothesis proposes lipid peroxidation as the initiating event, but the analysis relies on postmortem tissue from symptomatic or already-pathological brains. Whether peroxidation actually precedes detectable pathway disruption in living tissue cannot be determined from this data alone.

APOE4-specific vulnerability in homozygotes versus heterozygotes. The disulfide bridge hypothesis explains why APOE4 lacks protective crosslinking, but the analysis does not fully account for dose-dependent effects or why some APOE4 heterozygotes remain cognitively intact into advanced age.

Role of glial clearance systems. The hypothesis assumes that peroxidized lipids accumulating extracellularly drive the cascade, but the capacity and limitations of astrocytic and microglial clearance of HNE-ApoE and other lipid aldehydes remain incompletely characterized.

Reversibility and therapeutic windows. The hypothesis frames several molecular events as "irreversible" (pyrrole crosslinks, receptor trafficking arrest), but whether these are thermodynamically irreversible or merely require extreme cellular conditions to reverse is not established. The clinical therapeutic window — if interventions target lipid peroxidation before crosslink formation versus after — remains unknown.

Human-specific factors versus model organism limitations. While the analysis notes that human ApoER2 LA1-2 domains differ from rodents and may explain why transgenic models fail, a direct, mechanistic explanation for species-level differences in disulfide bridge formation and protective capacity is not provided.

Aβ monomer function in vivo. The reappraisal of Aβ as initially protective relies partly on in vitro antioxidant data and BACE1 stress-response upregulation. Whether Aβ monomers at physiological concentrations actually neutralize lipid aldehydes in the synaptic environment, and whether this function is adequate before plaque formation, requires direct evidence.

Alternative mechanisms for selective neuronal vulnerability. While ApoER2 expression correlates with early tau pathology, the analysis does not exclude other factors — such as intraneuronal amyloid accumulation in the same populations, neuronal morphology, synaptic connectivity density, metabolic state, or protective capacity of local glial environments — as contributors to regional selectivity.

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Conclusion

The lipid peroxidation and ApoER2–Dab1 disruption hypothesis integrates historical neuropathology, genetic risk, biochemical mechanisms, and anatomical specificity in a coherent framework. The APOE4 allele's structural inability to form disulfide bridges leaves its lipid cargo exposed to accelerated peroxidation. Reactive lipid aldehydes crosslink ApoE to ApoER2, disrupting receptor recycling and starving the Reelin–Dab1 pathway. This starvation removes inhibition on GSK3β and LIMK1, directly triggering tau hyperphosphorylation and synaptic disassembly in vulnerable neurons.

The hypothesis explains selective anatomical vulnerability through differential ApoER2 expression rather than prion-like spread — though, as Part V records, it is not the only account of that anatomy with human evidence behind it — and reframes Aβ as a protective response to lipid toxicity that becomes overwhelmed under chronic oxidative stress, which is the part of the framework the evidence least supports.

The framework accounts for features the amyloid cascade model failed to explain. It remains an integrative hypothesis requiring validation through in vivo studies demonstrating that lipid peroxidation precedes pathway disruption in living tissue, intervention studies showing that targeting peroxidation or receptor function arrests cognitive decline, and mechanistic studies clarifying the full pathway from ApoE crosslinking through kinase activation to synaptic disassembly.

Its strongest suit is the APOE effect, and the chemistry and anatomy that support it are worth pursuing on their own terms. Its weakest is the amyloid reappraisal, which the trial record and the Icelandic variant both press against, and which the rest of the framework does not need. The shift it argues for — from amyloid clearance alone toward lipid peroxidation and receptor signalling — survives the loss of that claim intact.

Works Cited

1. Ramsden CE, Keyes GS, Calzada E, Horowitz MS, Zamora D, Jahanipour J, et al.. Lipid Peroxidation Induced ApoE Receptor-Ligand Disruption as a Unifying Hypothesis Underlying Sporadic Alzheimer's Disease in Humans. J Alzheimers Dis 2022;87(3):1251-1290. DOI 10.3233/JAD-220071.

2. 2025 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2025;21(4). DOI 10.1002/alz.70235.

3. Kelliny S, Zhou XF, Bobrovskaya L. Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches. J Neurosci Res 2025;103(5):e70046. DOI 10.1002/jnr.70046.

4. Shi Y, Liao X, Yu G. Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease. ChemMedChem 2026;21(14):e70384. DOI 10.1002/cmdc.70384.

5. Twiss E, McPherson C, Weaver DF. Global Diseases Deserve Global Solutions: Alzheimer's Disease. Neurol Int 2025;17(6). DOI 10.3390/neurolint17060092.

6. Ferroptosis and Alzheimer's disease: a new insight into neurodegeneration. Frontiers in Immunology,, accessed March 30, 2026.

7. Ramsden CE, Cutler RG, Li X, Keyes GS. HYPOTHESIS: Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimer's disease in humans. Prostaglandins Leukot Essent Fatty Acids 2025;205:102681. DOI 10.1016/j.plefa.2025.102681.

8. Ramsden CE, Cutler RG, Li X, Keyes GS. Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimer's disease in humans. bioRxiv 2025. DOI 10.1101/2025.01.17.633633.

9. Ramsden CE, Cutler RG, Li X, Keyes GS. HYPOTHESIS: Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimer's disease in humans. Prostaglandins Leukot Essent Fatty Acids 2025;205:102681. DOI 10.1016/j.plefa.2025.102681.

10. THE ROLE OF MICROGLIAL-TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2) IN NEURONAL HOMEOSTASIS AND TAU PATHOGENESIS. IU Indianapolis ScholarWorks, accessed March 30, 2026.

    Find this paper

11. Prague: What Say You, Alois – Should It Be “Alzheimer-Fischer” Disease?. Journal of Alzheimer's Disease 2009;17(3):721-723. DOI 10.3233/jad-2009-1103.

12. Goedert M. Oskar Fischer and the study of dementia. Brain 2009;132(Pt 4):1102-11.awn256.

    Find this paper

13. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;3(77):77sr1. DOI 10.1126/scitranslmed.3002369.

14. Zeidman LA, Kondziella D. Re: Neuroscience in Nazi Europe part III: victims of the Third Reich. Can J Neurol Sci. 2012;39:729-746. Can J Neurol Sci 2013;40(3):433. PMID 24340700.

15. Ness AM, Aiken J. Gustav Oppenheim (1882-1937) and the Discovery of Cerebral Amyloid Angiopathy. Neuroscientist 2025;31(3):225-233. DOI 10.1177/10738584241251828.

16. Ramsden CE, Zamora D, Horowitz MS, Jahanipour J, Calzada E, Li X, et al.. ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer's disease. Acta Neuropathol Commun 2023;11(1):197. DOI 10.1186/s40478-023-01693-9.

17. Ferré-González L, Peña-Bautista C, Baquero M, Cháfer-Pericás C. Assessment of Lipid Peroxidation in Alzheimer's Disease Differential Diagnosis and Prognosis. Antioxidants (Basel) 2022;11(3). DOI 10.3390/antiox11030551.

18. Ramsden CE, Horowitz MS, Zamora D, Beach TG, Serrano GE, Arce RA, et al.. Evidence for ApoE receptor 2-Disabled homolog-1 pathway disruption in the amygdala in sporadic Alzheimer's disease. medRxiv 2025. DOI 10.1101/2025.06.13.25329511.

19. Lennol MP, Sánchez-Domínguez I, Cuchillo-Ibañez I, Camporesi E, Brinkmalm G, Alcolea D, et al.. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients. Alzheimers Res Ther 2022;14(1):161. DOI 10.1186/s13195-022-01108-2.

20. Elliott DA, Halliday GM, Garner B. Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neuroscience 2010;11(1). DOI 10.1186/1471-2202-11-23.

21. The Lipocalin Apolipoprotein D Functional Portrait: A Systematic Review. Frontiers in Physiology, DOI 10.3389/fphys.2021.738991, accessed March 30, 2026.

22. cuchillo Ibañez I. Review of: "Continual reelin signaling by the prime neurogenic niche of the adult brain". 2022. DOI 10.32388/447prl.

23. Serneels L, T'Syen D, Perez-Benito L, Theys T, Holt MG, De Strooper B. Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease. Mol Neurodegener 2020;15(1):60. DOI 10.1186/s13024-020-00399-z.

24. Targeting Brain ApoE Receptors for the Treatment of Alzheimer's Disease. BrightFocus, accessed March 30, 2026.

25. Ramsden CE, Keyes GS, Horowitz MS, et al. Lipid peroxidation induced ApoE receptor-ligand disruption as a unifying hypothesis underlying sporadic Alzheimer's disease. Oskar Fischer Prize submission 167, 2020. The origin of the protective-amyloid claim assessed in Parts IV and V.

26. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine 2023;388(1):9-21. DOI 10.1056/NEJMoa2212948.

27. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023;330(6):512-527. DOI 10.1001/jama.2023.13239.

28. Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017;549(7673):523-527. DOI 10.1038/nature24016. PMID 28959956.

29. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Aβ42 accumulation in human brain. American Journal of Pathology 2000;156(1):15-20. PMID 10623648.

30. Takahashi RH, Milner TA, Li F, et al. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. American Journal of Pathology 2002;161(5):1869-1879. PMID 12414533.

31. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. American Journal of Pathology 2000;157(1):277-286. PMID 10880397.

32. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-99. DOI 10.1038/nature11283. PMID 22801501.